Skip to main content
DYN
NASDAQ Life Sciences

Atlas Venture Files Intent to Sell $3.5M in Dyne Therapeutics Stock, Continuing Recent Distribution

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$23.232
Mkt Cap
$3.939B
52W Low
$8.06
52W High
$25
52W Position info
188% above low
Off High info
7.1% below high
Rel. Volume info
1.7× avg
Market data snapshot near publication time

DYN has more than doubled off its 52-week low of $8.06.

Summary

Atlas Venture, a major shareholder, plans to sell $3.52 million in Dyne Therapeutics stock, extending a recent trend of significant share dispositions totaling over $62 million in the last 90 days.


Key Events · Ownership and Investor Activity · DYN

  • Intent to Sell Shares

    Atlas Venture Fund XI, LP, a major shareholder, filed a Form 144 to sell 153,966 shares of common stock, valued at approximately $3.52 million.

  • Continuation of Share Distribution

    This proposed sale adds to a recent trend of significant share dispositions by Atlas Venture, which has sold over $62 million worth of Dyne Therapeutics stock in the past 90 days.

  • Institutional Shareholder Activity

    The shares were acquired via private placement in July 2020, indicating a long-term holding now being partially liquidated.


Analysis · DYN · Life Sciences

Atlas Venture, a significant institutional shareholder, has filed a Form 144 indicating its intent to sell an additional $3.52 million worth of Dyne Therapeutics common stock. This proposed sale continues a pattern of substantial share dispositions by Atlas Venture, which has sold over $62 million in shares over the past 90 days. While the current filing's value is modest relative to the company's market cap, the ongoing sales by a major investor could create an overhang on the stock.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, DYN was trading at $23.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.9B. The 52-week trading range was $8.06 to $25.00. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

DYN - Latest Insights

DYN
Nov 05, 2026, 7:25 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $18.63
Real-time Price: $17.99 info
Change: -$0.640 (-3%) info
Market Cap: $3.371B info
DYN
Sep 29, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $15.78
Real-time Price: $17.99 info
Change: +$2.21 (+14%) info
Market Cap: $3.371B info
DYN
Sep 29, 2026, 4:05 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $15.78
Real-time Price: $17.99 info
Change: +$2.21 (+14%) info
Market Cap: $3.371B info
DYN
Aug 17, 2026, 5:30 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $26.15
Real-time Price: $17.99 info
Change: -$8.16 (-31%) info
Market Cap: $3.371B info
DYN
Aug 14, 2026, 5:47 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $25.94
Real-time Price: $17.99 info
Change: -$7.95 (-31%) info
Market Cap: $3.371B info